179897-94-0Relevant articles and documents
HALOGENATED CATALYSTS COMPRISING SALAN LIGANDS
-
Page/Page column 47; 48, (2014/02/16)
Catalysts comprising a halogenated Salan ligand. Also disclosed are catalyst systems comprising the catalyst and an activator; methods to prepare the ligands, catalysts and catalyst systems; processes to polymerize olefins using the catalysts and/or catalyst systems; and the olefin polymers prepared according to the processes.
Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.
Kopka, Ihor E,Lin, Linus S,Mumford, Richard A,Lanza Jr., Thomas,Magriotis, Plato A,Young, David,DeLaszlo, Stephen E,MacCoss, Malcolm,Mills, Sander G,Van Riper, Gail,McCauley, Ermengilda,Lyons, Kathryn,Vincent, Stella,Egger, Linda A,Kidambi, Usha,Stearns, Ralph,Colletti, Adria,Teffera, Yohannes,Tong, Sharon,Owens, Karen,Levorse, Dorothy,Schmidt, John A,Hagmann, William K
, p. 2415 - 2418 (2007/10/03)
A series of substituted N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl- and (L)-azetidyl-beta-biaryl beta-alanine derivatives was prepared as selective and potent VLA-4 antagonists. The 2,6-dioxygenated biaryl substitution pattern is important for optimizing potency. Oral bioavailability was variable and may be a result of binding to circulating plasma proteins.
STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS
-
, (2008/06/13)
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.